14 results about "Neuronal Growth" patented technology

The application belongs to the field of medical biological materials, and relates to a preparation method of a hierarchical nanofiber composite film for nerve repair and application thereof. The method comprises the following steps: preparing multilayer nanofibers with different internal stresses through continuous multiple electrostatic spinning units, stacking the multilayer nanofibers with different internal stresses to form a composite nanofiber film with an internal stress gradient; chemically crosslinking the composite nanofiber film; performing adhesion molecule adhesion treatment on the upper surface of the composite nanofiber film; and preparing the hierarchical nanofiber composite film with an internal stress gradient and capable of self-deforming under the action of liquid to wrap nerves. The film provided by the application has excellent flexibility, biocompatibility and degradation performance, can efficiently and quickly adhere to the surface of damaged nerves, provides a good support microenvironment for nerve cell growth, promotes nerve regeneration and repair, and has a wide application prospect in the field of peripheral nerve injury repair.

The invention belongs to the technical field of biological medicine, and relates to application of a compound D25, in particular to application of a small molecule compound D25 in preparation of a product for preventing or treating Alzheimer's disease (AD), and the structural formula of the compound is shown in the specification. Experiments prove that the small molecule compound D25 can pass through a blood brain barrier, can induce autophagy, can relieve pathological characteristics of an AD mouse model and improve cognitive impairment of the AD mouse model, can reduce the proportion of disease-related microglial cells by recovering the morphology of the microglial cells and improving the A beta phagocytosis capacity of the microglial cells, has the potential of promoting neuronal growth and increasing the number of protrusions, and can be used for preparing a medicine for treating the disease-related microglial cells. Therefore, AD can be effectively treated, the safety is high, the effect is achieved, and the application prospect is great.

The present disclosure is directed to engineered cells designed to sense tau and to express one or more proteins in response to this binding event. In addition, the cells and associated methods of use can detect, treat, and recapitulate the symptoms of Alzheimer's disease. The engineered cells can regulate expression of neuronal growth factors and anti-inflammatory proteins to address neurodegeneration and neuroinflammation, respectively.

Disclosed herein are compounds, compositions, and methods for promoting neuronal growth and / or improving neuronal structure with the compounds and compositions disclosed herein. Also described are methods of treating diseases or disorders that are mediated by the loss of synaptic connectivity and / or plasticity, such as neurological diseases and disorders, with fused pyrrolidine psychoplastogens.

The present invention provides a medicine for treating a neurodegenerative disease, which employs LEFTY2 (Left-Right Determination Factor 2) generated by co-culturing mesenchymal stem cells of mammals with nerve cells having mutations in the APP (Amyloid precursor protein) gene, or a specific protein. The LEFTY2 has an effect of inhibiting Beta amyloid and a hyperphosphorylated neuronal microtubule-associated protein (Tau protein), without affecting the development of nerve cells and having the ability to promote the growth of the nerve cells; and the two types of proteins have a crucial impact on the neurodegenerative diseases.

The invention discloses an application of a connective tissue growth factor in preparation of a drug for promoting neuronal growth. The invention proposes and verifies that the connective tissue growth factor can promote the growth of neurons, realize effective regeneration of a nervous system and accelerate the recovery of sensory and motor functions for the first time; the adeno-associated virus expressing the connective tissue growth factor also has the same neuron growth promotion and nervous system regeneration effects, and can be widely applied to clinical treatment of related diseases with nerve regeneration requirements.

The invention relates to a PHA nerve scaffold based on degradable biological activity, a preparation method and application, polyhydroxyalkanoate is added into an organic solvent, and electrospinning is carried out after dissolution to obtain the PHA nerve scaffold based on degradable biological activity. In addition, mixing of other types of polymers is further introduced in the spinning process, so that the comprehensive performance is enhanced. Compared with the prior art, the PHA fiber material is obtained by controlling the viscosity of the polyhydroxyalkanoate solution, the injection speed and the rotating speed of a receiver, has a physical signal induction effect on the growth of nerve cells, can promote the growth of the nerve cells and the extension of axons when the material is degraded, and is beneficial to the regeneration of peripheral nerve injury. Meanwhile, other types of polymers are introduced, so that the fiber structure can be further changed, or the adaptability of the fiber to nerve cells can be enhanced. In addition, the preparation method provided by the invention is simple, convenient to operate and suitable for industrial production.

The invention discloses application of a gene expression enhancer in promotion of neuronal growth. The invention provides and verifies that the growth of neurons can be promoted by enhancing the expression of the microsome glutathione S transferase 3 gene for the first time, and the regeneration of a nervous system after injury and the recovery of sensory and motor functions are realized. The microsome glutathione S transferase 3 can be used as a new target of related drugs for diseases caused by nerve injury and neurodegenerative diseases, and has an excellent clinical application prospect.

This invention provides a polypeptide with neuroprotective effects and its applications. The novel polypeptide provided by this invention can resist the hydrolysis of peptidases in the intestinal microenvironment, can be effectively transported and absorbed by intestinal epithelial cells, improving oral bioavailability; it can penetrate the blood-brain barrier to reach target cells in the central nervous system, achieving targeted neurotrophic support; it can also significantly enhance the survival and differentiation capacity of nerve cells, promote nerve cell growth and development, and strengthen the neurotrophic support effect; ultimately, it provides the body with efficient, stable, safe, and convenient neurotrophic support, meeting the needs of different populations in scenarios such as neurohealth maintenance and nutritional supplementation, and promoting its large-scale application in the field of neurotrophic support.

The invention discloses an application of a leukocyte immunoglobulin-like receptor B4 in inhibition of neuronal growth. The invention proposes and verifies that the leukocyte immunoglobulin-like receptor B4 can effectively regulate neurons for the first time, an expression enhancer of the gene can significantly inhibit neuronal axon growth, and a new direction is provided for research and development of drugs for treating diseases caused by neuronal overgrowth.

The application provides a pharmaceutical composition for preventing and treating senile cognitive impairment with bipolar disorder, a preparation method and application thereof, and belongs to the technical field of medicines.The pharmaceutical composition prepared by mixing volatile oil separated from Acorus calamus and Ligusticum chuanxiong and water extract separated from Acorus calamus, Ligusticum chuanxiong, Astragalus and Polygala is rich in volatile oil and various water-soluble active ingredients.Based on the characteristics of promoting nerve cell growth and memory impairment repair of the pharmaceutical composition, the application also provides application of the pharmaceutical composition in preparation of medicines for preventing and / or treating senile cognitive impairment and / or bipolar disorder.

Disclosed herein are compounds, compositions, and methods for promoting neuronal growth and / or improving neuronal structure with the compounds and compositions disclosed herein. Also described are methods of treating diseases or disorders that are mediated by the loss of synaptic connectivity and / or plasticity, such as neurological diseases and disorders, with non-hallucinogenic psychoplastogens.

The invention discloses application of fibroblasts in preparation of a medicine for inhibiting nerve cell growth, and belongs to the technical field of biological medicine. Researches find that the fibroblasts can inhibit proliferation and differentiation of neural progenitor cells in vitro and also can inhibit growth of mature nerve cells, and obvious inhibition of nerves can be observed in an in-vivo mouse intervertebral disc degeneration model, so that the fibroblasts can be used for inhibiting abnormal ingrowth of nerves in the intervertebral disc degeneration process and relieving intervertebral disc degeneration.

The present disclosure generally relates to novel chimeric antigen receptors (“CARs”), modified regulatory T cells (“Tregs”) expressing such CARs and / or Tregs which are engineered to express neurodegenerative disease modifying molecules, e.g., which express molecules which prevent oxidative / inflammatory activity, or which promote neuronal growth / survival such as nerve growth factors or non-classical neurotrophic factors. The present disclosure also generally relates to compositions containing such modified Tregs, and methods of use thereof as therapeutics, in particular for treating and preventing neurodegenerative diseases and symptoms associated with therewith, and / or for slowing the onset of such neurodegenerative diseases, particularly in persons at risk because of genetic factors or in persons exhibiting early signs of developing such a neurodegenerative disease.